Cytori Therapeutics Inc (CYTX)

1.01
NASDAQ : Health Care
Prev Close 1.05
Day Low/High 1.01 / 1.07
52 Wk Low/High 0.98 / 5.44
Avg Volume 670.60K
Exchange NASDAQ
Shares Outstanding 23.64M
Market Cap 24.83M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cytori Provides Latest Corporate Update At The 2nd Annual Disruptive Growth & Healthcare Conference

Cytori Provides Latest Corporate Update At The 2nd Annual Disruptive Growth & Healthcare Conference

Presentation on February 15, 2017 at 11:15 AM Eastern Time

GNC Plummets, Mallinckrodt Regains Ground Ahead of Market's Open

GNC Plummets, Mallinckrodt Regains Ground Ahead of Market's Open

Here's how biotech and healthcare stocks are moving ahead of market's open.

Cytori Therapeutics To Provide Corporate Update At 2017 Biotech Showcase™

Cytori Therapeutics To Provide Corporate Update At 2017 Biotech Showcase™

Presentation on January 10, 2016 at 4:00 PM Pacific Time

Cytori Strengthens Global Intellectual Property Portfolio With Key Patents

Cytori Strengthens Global Intellectual Property Portfolio With Key Patents

Cytori Therapeutics, Inc. (NASDAQ: CYTX) ("Cytori" or the "Company") announced today the issuance of a number of key patents that strengthen its intellectual property portfolio in the U.

Cytori Granted FDA Orphan Drug Designation For ECCS-50 In Scleroderma

Cytori Granted FDA Orphan Drug Designation For ECCS-50 In Scleroderma

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted Cytori an orphan drug designation for cryopreserved or centrally processed ECCS-50 for...

Cytori Reports Third Quarter 2016 Business And Financial Results

Cytori Reports Third Quarter 2016 Business And Financial Results

Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its third quarter financial results and provided updates on its corporate activity and clinical development.

Cytori To Present Data In Two Distinct Models Of Impaired Wound Healing

Cytori To Present Data In Two Distinct Models Of Impaired Wound Healing

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present new preclinical data describing positive effects of Cytori Cell Therapy™ on a corneal wound healing model and in cutaneous scarring following burn injury.

Cytori To Webcast Third Quarter Financial Results On November 9

Cytori To Webcast Third Quarter Financial Results On November 9

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Wednesday, November 9, 2016 at 5:30 PM Eastern Time.

Cytori Presents Scleroderma Clinical Trial Data At The 2016 American College Of Rheumatology Annual Meeting

Cytori Presents Scleroderma Clinical Trial Data At The 2016 American College Of Rheumatology Annual Meeting

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will present data from its STAR Phase 3 clinical trial describing progress, preliminary blinded patient characteristics, and safety of adipose-derived regenerative cells...

Cytori Publication On Cytori Cell Therapy For Combined Radiation And Thermal Injury

Cytori Publication On Cytori Cell Therapy For Combined Radiation And Thermal Injury

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication of preclinical safety and efficacy study data using Cytori Cell Therapy™ for combined radiation and thermal injury.

BARDA Increases Contract Option With Cytori To Advance Countermeasure Clinical Trial

BARDA Increases Contract Option With Cytori To Advance Countermeasure Clinical Trial

Cytori Therapeutics (NASDAQ: CYTX) (the "Company") today announced that the Company and Biomedical Advanced Research and Development Authority (BARDA), a division of the U.

Cytori To Present In Investor Events In September 2016

Cytori To Present In Investor Events In September 2016

Cytori Therapeutics, Inc. (NASDAQ: CYTX), a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, announced today that management will...

Cytori Therapeutics Receives Frost & Sullivan 2016 Technology Innovation Award

Cytori Therapeutics Receives Frost & Sullivan 2016 Technology Innovation Award

Cytori Therapeutics, Inc. (NASDAQ: CYTX) ("Cytori" or the "Company") today announced that it has received the Frost & Sullivan 2016 Technology Innovation Award in recognition of advancements made in the field of...